Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90

1.

A preliminary analysis of interleukin-1 ligands as potential predictive biomarkers of response to cetuximab.

Espinosa-Cotton M, Fertig EJ, Stabile LP, Gaither-Davis A, Bauman JE, Schmitz S, Gibson-Corley KN, Cheng Y, Jensen IJ, Badovinac VP, Laux D, Simons AL.

Biomark Res. 2019 Jul 16;7:14. doi: 10.1186/s40364-019-0164-0. eCollection 2019.

2.

Molecular and Clinical Activity of CDX-3379, an Anti-ErbB3 Monoclonal Antibody, in Head and Neck Squamous Cell Carcinoma.

Duvvuri U, George J, Kim S, Alvarado D, Neumeister VM, Chenna A, Gedrich R, Hawthorne T, LaVallee T, Grandis JR, Bauman JE.

Clin Cancer Res. 2019 Jul 15. doi: 10.1158/1078-0432.CCR-18-3453. [Epub ahead of print]

PMID:
31308059
3.

Circulating exosomes measure responses to therapy in head and neck cancer patients treated with cetuximab, ipilimumab, and IMRT.

Theodoraki MN, Yerneni S, Gooding WE, Ohr J, Clump DA, Bauman JE, Ferris RL, Whiteside TL.

Oncoimmunology. 2019 Apr 24;8(7):1593805. doi: 10.1080/2162402X.2019.1593805. eCollection 2019.

4.

Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for PIK3CA-altered head and neck cancer.

Hedberg ML, Peyser ND, Bauman JE, Gooding WE, Li H, Bhola NE, Zhu TR, Zeng Y, Brand TM, Kim MO, Jordan RCK, VandenBerg S, Olivas V, Bivona TG, Chiosea SI, Wang L, Mills GB, Johnson JT, Duvvuri U, Ferris RL, Ha P, Johnson DE, Grandis JR.

J Exp Med. 2019 Feb 4;216(2):419-427. doi: 10.1084/jem.20181936. Epub 2019 Jan 25.

5.

Long term follow-up of neoadjuvant chemotherapy for non-small cell lung cancer (NSCLC) investigating early positron emission tomography (PET) scan as a predictor of outcome.

Romine PE, Martins RG, Eaton KD, Wood DE, Behnia F, Goulart BHL, Mulligan MS, Wallace SG, Kell E, Bauman JE, Patel SA, Vesselle HJ.

BMC Cancer. 2019 Jan 14;19(1):70. doi: 10.1186/s12885-019-5284-2.

6.

Behavioral and endocrine correlates of dominance in captive female Jackson's hartebeest (Alcelaphus buselaphus).

Spratt KS, Spratt JS, Bauman JE, Chandler CR.

Zoo Biol. 2019 Mar;38(2):157-166. doi: 10.1002/zoo.21462. Epub 2018 Dec 13.

PMID:
30548871
7.

Current Concepts in Chemotherapy for Head and Neck Cancer.

Sindhu SK, Bauman JE.

Oral Maxillofac Surg Clin North Am. 2019 Feb;31(1):145-154. doi: 10.1016/j.coms.2018.09.003. Review.

PMID:
30449525
8.

Phase 1 study of EGFR-antisense DNA, cetuximab, and radiotherapy in head and neck cancer with preclinical correlatives.

Bauman JE, Duvvuri U, Thomas S, Gooding WE, Clump DA, Karlovits B, Wehbe A, Miller FR, Kim S, Sen M, Heron DE, Grandis JR, Argiris A.

Cancer. 2018 Oct 1;124(19):3881-3889. doi: 10.1002/cncr.31651. Epub 2018 Oct 6.

PMID:
30291796
9.

Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial.

Ferris RL, Saba NF, Gitlitz BJ, Haddad R, Sukari A, Neupane P, Morris JC, Misiukiewicz K, Bauman JE, Fenton M, Jimeno A, Adkins DR, Schneider CJ, Sacco AG, Shirai K, Bowles DW, Gibson M, Nwizu T, Gottardo R, Manjarrez KL, Dietsch GN, Bryan JK, Hershberg RM, Cohen EEW.

JAMA Oncol. 2018 Nov 1;4(11):1583-1588. doi: 10.1001/jamaoncol.2018.1888.

10.

THE FIRST REPORT OF A CROTALID ENVENOMATION IN A DOMESTICATED FERRET ( MUSTELA FURO) AND SUCCESSFUL TREATMENT WITH A NOVEL F(AB')2 ANTIVENOM.

Loredo AI, Bauman JE, Wells RJ.

J Zoo Wildl Med. 2018 Jun;49(2):497-500. doi: 10.1638/2017-0141.1.

PMID:
29900771
11.

Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer.

Brand TM, Hartmann S, Bhola NE, Li H, Zeng Y, O'Keefe RA, Ranall MV, Bandyopadhyay S, Soucheray M, Krogan NJ, Kemp C, Duvvuri U, LaVallee T, Johnson DE, Ozbun MA, Bauman JE, Grandis JR.

Cancer Res. 2018 May 1;78(9):2383-2395. doi: 10.1158/0008-5472.CAN-17-1672. Epub 2018 Feb 12.

12.

Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals.

Shayan G, Kansy BA, Gibson SP, Srivastava RM, Bryan JK, Bauman JE, Ohr J, Kim S, Duvvuri U, Clump DA, Heron DE, Johnson JT, Hershberg RM, Ferris RL.

Clin Cancer Res. 2018 Jan 1;24(1):62-72. doi: 10.1158/1078-0432.CCR-17-0357. Epub 2017 Oct 23.

13.

When the Damage Is Done: Selecting Patients for Head and Neck Cancer Chemoprevention Trials.

Johnson DE, Bauman JE.

Cancer Prev Res (Phila). 2017 Sep;10(9):489-490. doi: 10.1158/1940-6207.CAPR-17-0197. Epub 2017 Aug 18. No abstract available.

14.

IL6 is associated with response to dasatinib and cetuximab: Phase II clinical trial with mechanistic correlatives in cetuximab-resistant head and neck cancer.

Stabile LP, Egloff AM, Gibson MK, Gooding WE, Ohr J, Zhou P, Rothenberger NJ, Wang L, Geiger JL, Flaherty JT, Grandis JR, Bauman JE.

Oral Oncol. 2017 Jun;69:38-45. doi: 10.1016/j.oraloncology.2017.03.011. Epub 2017 Apr 9.

15.

Increased PD-1+ and TIM-3+ TILs during Cetuximab Therapy Inversely Correlate with Response in Head and Neck Cancer Patients.

Jie HB, Srivastava RM, Argiris A, Bauman JE, Kane LP, Ferris RL.

Cancer Immunol Res. 2017 May;5(5):408-416. doi: 10.1158/2326-6066.CIR-16-0333. Epub 2017 Apr 13.

16.

Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer.

Bauman JE, Duvvuri U, Gooding WE, Rath TJ, Gross ND, Song J, Jimeno A, Yarbrough WG, Johnson FM, Wang L, Chiosea S, Sen M, Kass J, Johnson JT, Ferris RL, Kim S, Hirsch FR, Ellison K, Flaherty JT, Mills GB, Grandis JR.

JCI Insight. 2017 Mar 23;2(6):e90449. doi: 10.1172/jci.insight.90449.

17.

E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group.

Marur S, Li S, Cmelak AJ, Gillison ML, Zhao WJ, Ferris RL, Westra WH, Gilbert J, Bauman JE, Wagner LI, Trevarthen DR, Balkrishna J, Murphy BA, Agrawal N, Colevas AD, Chung CH, Burtness B.

J Clin Oncol. 2017 Feb 10;35(5):490-497. doi: 10.1200/JCO.2016.68.3300. Epub 2016 Dec 28.

18.

Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting.

Bauman JE, Cohen E, Ferris RL, Adelstein DJ, Brizel DM, Ridge JA, O'Sullivan B, Burtness BA, Butterfield LH, Carson WE, Disis ML, Fox BA, Gajewski TF, Gillison ML, Hodge JW, Le QT, Raben D, Strome SE, Lynn J, Malik S.

Cancer. 2017 Apr 1;123(7):1259-1271. doi: 10.1002/cncr.30449. Epub 2016 Dec 1.

19.

Phase II trial of post-operative radiotherapy with concurrent cisplatin plus panitumumab in patients with high-risk, resected head and neck cancer.

Ferris RL, Geiger JL, Trivedi S, Schmitt NC, Heron DE, Johnson JT, Kim S, Duvvuri U, Clump DA, Bauman JE, Ohr JP, Gooding WE, Argiris A.

Ann Oncol. 2016 Dec;27(12):2257-2262. doi: 10.1093/annonc/mdw428. Epub 2016 Oct 11.

20.

Association of pretreatment body mass index and survival in human papillomavirus positive oropharyngeal squamous cell carcinoma.

Albergotti WG, Davis KS, Abberbock S, Bauman JE, Ohr J, Clump DA, Heron DE, Duvvuri U, Kim S, Johnson JT, Ferris RL.

Oral Oncol. 2016 Sep;60:55-60. doi: 10.1016/j.oraloncology.2016.07.003. Epub 2016 Jul 7. Review.

21.

Subsets of salivary duct carcinoma defined by morphologic evidence of pleomorphic adenoma, PLAG1 or HMGA2 rearrangements, and common genetic alterations.

Chiosea SI, Thompson LD, Weinreb I, Bauman JE, Mahaffey AM, Miller C, Ferris RL, Gooding WE.

Cancer. 2016 Oct 15;122(20):3136-3144. doi: 10.1002/cncr.30179. Epub 2016 Jul 5.

22.

Prevention of Carcinogen-Induced Oral Cancer by Sulforaphane.

Bauman JE, Zang Y, Sen M, Li C, Wang L, Egner PA, Fahey JW, Normolle DP, Grandis JR, Kensler TW, Johnson DE.

Cancer Prev Res (Phila). 2016 Jul;9(7):547-57. doi: 10.1158/1940-6207.CAPR-15-0290. Epub 2016 Jun 23.

23.

Risk of Severe Toxicity According to Site of Recurrence in Patients Treated With Stereotactic Body Radiation Therapy for Recurrent Head and Neck Cancer.

Ling DC, Vargo JA, Ferris RL, Ohr J, Clump DA, Yau WW, Duvvuri U, Kim S, Johnson JT, Bauman JE, Branstetter BF, Heron DE.

Int J Radiat Oncol Biol Phys. 2016 Jul 1;95(3):973-980. doi: 10.1016/j.ijrobp.2016.02.049.

PMID:
27302512
24.

Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma.

Geiger JL, Bauman JE, Gibson MK, Gooding WE, Varadarajan P, Kotsakis A, Martin D, Gutkind JS, Hedberg ML, Grandis JR, Argiris A.

Head Neck. 2016 Dec;38(12):1759-1764. doi: 10.1002/hed.24501. Epub 2016 May 27.

PMID:
27232378
25.

Phase II randomized trial of radiation therapy, cetuximab, and pemetrexed with or without bevacizumab in patients with locally advanced head and neck cancer.

Argiris A, Bauman JE, Ohr J, Gooding WE, Heron DE, Duvvuri U, Kubicek GJ, Posluszny DM, Vassilakopoulou M, Kim S, Grandis JR, Johnson JT, Gibson MK, Clump DA, Flaherty JT, Chiosea SI, Branstetter B, Ferris RL.

Ann Oncol. 2016 Aug;27(8):1594-600. doi: 10.1093/annonc/mdw204. Epub 2016 May 13.

26.

Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma.

Hedberg ML, Goh G, Chiosea SI, Bauman JE, Freilino ML, Zeng Y, Wang L, Diergaarde BB, Gooding WE, Lui VW, Herbst RS, Lifton RP, Grandis JR.

J Clin Invest. 2016 Apr 1;126(4):1606. doi: 10.1172/JCI86862. Epub 2016 Apr 1. No abstract available.

27.

The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations.

Geiger JL, Grandis JR, Bauman JE.

Oral Oncol. 2016 May;56:84-92. doi: 10.1016/j.oraloncology.2015.11.022. Epub 2015 Dec 28. Review.

28.

Proteomic Characterization of Head and Neck Cancer Patient-Derived Xenografts.

Li H, Wheeler S, Park Y, Ju Z, Thomas SM, Fichera M, Egloff AM, Lui VW, Duvvuri U, Bauman JE, Mills GB, Grandis JR.

Mol Cancer Res. 2016 Mar;14(3):278-86. doi: 10.1158/1541-7786.MCR-15-0354. Epub 2015 Dec 18.

29.

Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma.

Hedberg ML, Goh G, Chiosea SI, Bauman JE, Freilino ML, Zeng Y, Wang L, Diergaarde BB, Gooding WE, Lui VW, Herbst RS, Lifton RP, Grandis JR.

J Clin Invest. 2016 Jan;126(1):169-80. doi: 10.1172/JCI82066. Epub 2015 Nov 30. Erratum in: J Clin Invest. 2016 Apr 1;126(4):1606.

30.

Oral Cancer Chemoprevention--The End of EPOC, the Beginning of an Epoch of Molecular Selection.

Bauman JE, Grandis J.

JAMA Oncol. 2016 Feb;2(2):178-9. doi: 10.1001/jamaoncol.2015.4637. No abstract available.

PMID:
26540592
31.

An enhanced role for palliative care in the multidisciplinary approach to high-risk head and neck cancer.

Schenker Y, Arnold RM, Bauman JE, Heron DE, Johnson JT.

Cancer. 2016 Feb 1;122(3):340-3. doi: 10.1002/cncr.29754. Epub 2015 Oct 27. No abstract available.

32.

Primary RET-mutated lung neuroendocrine carcinoma in MEN2B: response to RET-targeted therapy.

Geiger JL, Chiosea SI, Challinor SM, Nikiforova MN, Bauman JE.

Endocr Relat Cancer. 2015 Oct;22(5):L19-22. doi: 10.1530/ERC-15-0307. Epub 2015 Aug 18. No abstract available.

PMID:
26285607
33.

Persistent Salivary Human Papillomavirus DNA as a Surveillance Biomarker: Not Just Spitting in the Wind.

Bauman JE, Ferris RL.

JAMA Oncol. 2015 Oct;1(7):915-7. doi: 10.1001/jamaoncol.2015.2606. No abstract available.

PMID:
26226055
34.

Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.

Van Allen EM, Lui VW, Egloff AM, Goetz EM, Li H, Johnson JT, Duvvuri U, Bauman JE, Stransky N, Zeng Y, Gilbert BR, Pendleton KP, Wang L, Chiosea S, Sougnez C, Wagle N, Zhang F, Du Y, Close D, Johnston PA, McKenna A, Carter SL, Golub TR, Getz G, Mills GB, Garraway LA, Grandis JR.

JAMA Oncol. 2015 May;1(2):238-44. doi: 10.1001/jamaoncol.2015.34.

35.

Cancer of the oropharynx.

Clump DA, Bauman JE, Ferris RL.

Surg Oncol Clin N Am. 2015 Jul;24(3):509-20. doi: 10.1016/j.soc.2015.03.014. Epub 2015 Apr 15. Review.

PMID:
25979397
36.

Chemoprevention targets for tobacco-related head and neck cancer: past lessons and future directions.

Sheth SH, Johnson DE, Kensler TW, Bauman JE.

Oral Oncol. 2015 Jun;51(6):557-64. doi: 10.1016/j.oraloncology.2015.02.101. Epub 2015 Apr 11. Review.

PMID:
25868717
37.

Molecular characterization of apocrine salivary duct carcinoma.

Chiosea SI, Williams L, Griffith CC, Thompson LD, Weinreb I, Bauman JE, Luvison A, Roy S, Seethala RR, Nikiforova MN.

Am J Surg Pathol. 2015 Jun;39(6):744-52. doi: 10.1097/PAS.0000000000000410.

PMID:
25723113
38.

A prospective phase 2 trial of reirradiation with stereotactic body radiation therapy plus cetuximab in patients with previously irradiated recurrent squamous cell carcinoma of the head and neck.

Vargo JA, Ferris RL, Ohr J, Clump DA, Davis KS, Duvvuri U, Kim S, Johnson JT, Bauman JE, Gibson MK, Branstetter BF, Heron DE.

Int J Radiat Oncol Biol Phys. 2015 Mar 1;91(3):480-8. doi: 10.1016/j.ijrobp.2014.11.023. Epub 2015 Jan 30.

PMID:
25680594
39.

A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer.

Jimeno A, Bauman JE, Weissman C, Adkins D, Schnadig I, Beauregard P, Bowles DW, Spira A, Levy B, Seetharamu N, Hausman D, Walker L, Rudin CM, Shirai K.

Oral Oncol. 2015 Apr;51(4):383-8. doi: 10.1016/j.oraloncology.2014.12.013. Epub 2015 Jan 13.

40.

A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma.

Galloway TJ, Wirth LJ, Colevas AD, Gilbert J, Bauman JE, Saba NF, Raben D, Mehra R, Ma AW, Atoyan R, Wang J, Burtness B, Jimeno A.

Clin Cancer Res. 2015 Apr 1;21(7):1566-73. doi: 10.1158/1078-0432.CCR-14-2820. Epub 2015 Jan 8.

41.

CHK it out! Blocking WEE kinase routs TP53 mutant cancer.

Bauman JE, Chung CH.

Clin Cancer Res. 2014 Aug 15;20(16):4173-5. doi: 10.1158/1078-0432.CCR-14-0720.

42.

Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma.

Krug LM, Wozniak AJ, Kindler HL, Feld R, Koczywas M, Morero JL, Rodriguez CP, Ross HJ, Bauman JE, Orlov SV, Ruckdeschel JC, Mita AC, Fein L, He X, Hall R, Kawabe T, Sharma S.

Lung Cancer. 2014 Sep;85(3):429-34. doi: 10.1016/j.lungcan.2014.06.008. Epub 2014 Jul 5.

PMID:
25047675
43.

A randomized, phase 2 trial of Docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic non-small-cell lung cancer.

Levy B, Spira A, Becker D, Evans T, Schnadig I, Camidge DR, Bauman JE, Hausman D, Walker L, Nemunaitis J, Rudin CM, Halmos B, Bowles DW.

J Thorac Oncol. 2014 Jul;9(7):1031-5. doi: 10.1097/JTO.0000000000000183.

44.

A clinical algorithm for fine-needle aspiration molecular testing effectively guides the appropriate extent of initial thyroidectomy.

Yip L, Wharry LI, Armstrong MJ, Silbermann A, McCoy KL, Stang MT, Ohori NP, LeBeau SO, Coyne C, Nikiforova MN, Bauman JE, Johnson JT, Tublin ME, Hodak SP, Nikiforov YE, Carty SE.

Ann Surg. 2014 Jul;260(1):163-8. doi: 10.1097/SLA.0000000000000215.

PMID:
24901361
45.

Targeting secondary immune responses to cetuximab: CD137 and the outside story.

Bauman JE, Grandis JR.

J Clin Invest. 2014 Jun;124(6):2371-5. doi: 10.1172/JCI76264. Epub 2014 May 16.

46.

Salivary duct carcinoma and the concept of early carcinoma ex pleomorphic adenoma.

Griffith CC, Thompson LD, Assaad A, Purgina BM, Lai C, Bauman JE, Weinreb I, Seethala RR, Chiosea SI.

Histopathology. 2014 Dec;65(6):854-60. doi: 10.1111/his.12454. Epub 2014 Oct 30.

PMID:
24804831
47.

Erlotinib, erlotinib-sulindac versus placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancer.

Gross ND, Bauman JE, Gooding WE, Denq W, Thomas SM, Wang L, Chiosea S, Hood BL, Flint MS, Sun M, Conrads TP, Ferris RL, Johnson JT, Kim S, Argiris A, Wirth L, Nikiforova MN, Siegfried JM, Grandis JR.

Clin Cancer Res. 2014 Jun 15;20(12):3289-98. doi: 10.1158/1078-0432.CCR-13-3360. Epub 2014 Apr 11.

48.

Human papillomavirus-associated adenocarcinoma of the base of tongue: potentially actionable genetic changes.

Chang AM, Nikiforova MN, Johnson JT, Bauman JE, Perez-Ordonez B, Seethala RR, Krane JF, Chiosea SI.

Head Neck Pathol. 2014 Jun;8(2):151-6. doi: 10.1007/s12105-013-0508-2. Epub 2013 Nov 21.

49.

Integrating novel therapeutic monoclonal antibodies into the management of head and neck cancer.

Bauman JE, Ferris RL.

Cancer. 2014 Mar 1;120(5):624-32. doi: 10.1002/cncr.28380. Epub 2013 Nov 12. Review.

50.

Upregulation of the ATR-CHEK1 pathway in oral squamous cell carcinomas.

Parikh RA, Appleman LJ, Bauman JE, Sankunny M, Lewis DW, Vlad A, Gollin SM.

Genes Chromosomes Cancer. 2014 Jan;53(1):25-37. doi: 10.1002/gcc.22115. Epub 2013 Oct 21.

Supplemental Content

Loading ...
Support Center